Plain-English translation of NCT05909332 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether BP102, a new medication that blocks blood vessel growth in tumors, can help prevent breast cancer from coming back when given alongside standard . Women who have had surgery for triple-negative breast cancer will either receive plus BP102, or alone. The goal is to see if adding the medication improves outcomes for this aggressive type of breast cancer.
Triple-negative breast cancer is harder to treat because standard hormone and HER2-targeted therapies don't work for it. Researchers hope that this medication, which cuts off blood supply to tumors, might work better when combined with to keep the cancer from returning.
You likely qualify if…
You likely don't qualify if…
If you join, you'll receive either plus BP102 or alone (decided randomly). The involves two phases: first, two drugs given every two weeks for 4 doses, followed by a third drug given weekly for 4 weeks. If you're in the medication group, you'll also receive BP102 infusions twice a month for a full year. You'll have regular clinic visits for treatment, blood tests, and monitoring. The entire commitment lasts about one year from your first dose.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China